Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor

Journal of Neurosurgery

Volumn 84, Issue 6, 1996, Pages 1024-1032

  Pollack, Ian F ^a,b   Kawecki, Stephanie ^a   Lazo, John S ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

7 hydroxystaurosporine; astrocytoma; glioma; growth inhibition; protein kinase C; signal transduction

Indexed keywords

7 HYDROXYSTAUROSPORINE; CARMUSTINE; CISPLATIN; PROTEIN KINASE C; PROTEIN KINASE INHIBITOR;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER GRAFT; CANCER INHIBITION; CLONOGENESIS; CONTROLLED STUDY; CYTOSTASIS; DRUG CYTOTOXICITY; DRUG POTENTIATION; ENZYME INHIBITION; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0029938768     PISSN: 00223085     EISSN: None     Source Type: Journal    
DOI: 10.3171/jns.1996.84.6.1024     Document Type: Article

References (43)

1. Akinaga S, Gomi K, Morimoto M, et al: Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Res 51:4888-4892, 1991
2. Akinaga S, Nomura K, Gomi K, et al: Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C. Cancer Chemother Pharmacol 32:183-189, 1993
3. Akinaga S, Nomura K, Gomi K, et al: Synergistic anti-tumor effect of UCN-01, a protein kinase (C) inhibitor, combined with various anti-cancer agents. Proc Am Assoc Cancer Res 33: 514, 1992 (Abstract)
4. Baltuch G, Shenouda G, Langleben A, et al: High dose tamoxifen in the treatment of recurrent high grade glioma: a report of clinical stabilization and tumour regression. Can J Neurol Sci 20:168-170, 1993
5. Baltuch GH, Couldwell WT, Villemure JG, et al: Protein kinase C inhibitors suppress cell growth in established and low-passage glioma cell lines. A comparison between staurosporine and tamoxifen. Neurosurgery 33:495-501, 1993
6. Barry MA, Behnke CA, Eastman A: Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol 40:2353-2362, 1990
7. Basu A, Lazo JS: Sensitization of human cervical carcinoma cells to cis-diamminedichloroplatinum(II) by bryostatin 1. Cancer Res 52:3119-3124, 1992
8. Benzil DL, Finkelstein SD, Epstein MH, et al: Expression pattern of α-protein kinase C in human astrocytomas indicates a role in malignant progression. Cancer Res 52:2951-2956, 1992
9. Bit RA, Davis PD, Elliott LH, et al: Inhibitors of protein kinase C. 3. Potent and highly selective bisindolylmaleimides by conformational restriction. J Med Chem 36:21-29, 1993
10. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254, 1976
11. Chou J, Chou TC: Dose-Effect Analysis with Microcomputers. Cambridge, England: BIOSOFT, 1987, pp 19-64
12. Chou TC, Talalay P: Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur J Biochem 115:207-216, 1981
13. Chou TC, Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55, 1984
14. Couldwell WT, Antel JP, Yong VW: Protein kinase C activity correlates with the growth rate of malignant gliomas: Part II. Effects of glioma mitogens and modulators of protein kinase C. Neurosurgery 31:717-724, 1992
15. Couldwell WT, Gopalakrishna R, Hinton DR, et al: Hypericin: a potential antiglioma therapy. Neurosurgery 35:705-710, 1994
16. Couldwell WT, Uhm JH, Antel JP, et al: Enhanced protein kinase C activity correlates with the growth rate of malignant gliomas in vitro. Neurosurgery 29:880-887, 1991
17. Couldwell WT, Weiss MH, DeGiorgio CM, et al: Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen. Neurosurgery 32:485-490, 1993
18. Davis PD, Hill CH, Keech E, et al: Potent selective inhibitors of protein kinase C. FEBS Lett 259:61-63, 1989
19. Gschwendt M, Kittstein W, Marks F: A novel type of phorbol ester-dependent protein phosphorylation in the particulate fraction of mouse epidermis. Biochem Biophys Res Commun 137:766-774, 1986
20. Haimovitz-Friedman A, Balaban N, McLoughlin M, et al: Protein kinase C mediates basic fibroblast growth factor protection of endothelial cells against radiation-induced apoptosis. Cancer Res 54:2591-2597, 1994
21. Hofmann J, Doppler W, Jakob A, et al: Enhancement of the antiproliferative effect of cis-diamminedichloroplatinum (II) and nitrogen mustard by inhibitors of protein kinase C. Int J Cancer 42:382-388, 1988
22. Hofmann J, Ueberall F, Posch L. et al: Synergistic enhancement of the antiproliferative activity of cis-diamminedichloroplatinum(II) by the ether lipid analogue BM41440, an inhibitor of protein kinase C. Lipids 24:312-317, 1989
23. House C, Kemp BE: Protein kinase C contains a pseudosubstrate prototype in its regulatory domain. Science 238: 1726-1728, 1987
24. Meyer T, Regenass U, Fabbro D, et al: A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity. Int J Cancer 43:851-856, 1989
25. Nishizuka Y: Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 258:607-613, 1992
26. Nishizuka Y: Studies and prospectives of the protein kinase C family for cellular regulation. Cancer 63:1892-1903, 1989
27. Pollack IF, Randall MS, Kristofik MP, et al: Effect of tamoxifen on DNA synthesis and proliferation of human malignant glioma lines in vitro. Cancer Res 50:7134-7138, 1990
28. Pollack IF, Randall MS, Kristofik MP, et al: Response of low-passage human malignant gliomas in vitro to stimulation and selective inhibition of growth factor-mediated pathways. J Neurosurg 75:284-293, 1991
29. Pollack IF, Randall MS, Kristofik MP, et al: Response of malignant glioma cell lines to activation and inhibition of protein kinase C-mediated pathways. J Neurosurg 73:98-105, 1990
30. 1H-MR spectroscopic imaging. J Neurosurg 80:413 A, 1994 (Abstract)
31. + antiporter in suppression of apoptosis by granulocyte macrophage colony-stimulating factor and interleukin-3. J Biol Chem 267:9980-9987, 1992
32. Reifenberger O, Deckert M, Wechsler W: Immunohistochemical determination of protein kinase C expression and proliferative activity in human brain tumors. Acta Neuropathol 78: 166-175, 1989
33. Riss TL, Moravec RA: Comparison of MTT, XTT, and a novel tetrazolium compound MTS for in vitro proliferation and chemosensitivity assays. Mol Biol Cell 3 (Suppl):184a. 1992 (Abstract)
34. Seynaeve CM, Kazanietz MG, Blumberg PM, et al: Differential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue. Mol Pharmacol 45:1207-1214, 1994
35. Seynaeve CM, Stetler-Stevenson M, Sehers S, et al: Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells. Cancer Res 53: 2081-2086, 1993
36. Takahashi I, Kobayashi E, Asano K, et al: UCN-01, a selective inhibitor of protein kinase C from streptomyces. J Antibiot 40: 1782-1784, 1987 (Letter)
37. Takahashi I, Saitoh Y, Yoshida M, et al: UCN-01 and UCN-02, new selective inhibitors of protein kinase C. II. Purification, physio-chemical properties, structural determinations, and biological activities. J Antibiot 42:571-576, 1989
38. Todo T, Shitara N, Nakamura H, et al: Immunohistochemical demonstration of protein kinase C isozymes in human brain tumors. Neurosurgery 29:399-404, 1991
39. Vertosick FT Jr, Selker RG, Arena V: A dose-escalation study of tamoxifen therapy in patients with recurrent glioblastoma multiforme. J Neurosurg 80:385A, 1994 (Abstract)
40. Vertosick FT Jr, Selker RG, Pollack IF, et al: The treatment of intracranial malignant gliomas using orally administered lamoxifen therapy: preliminary results in a series of "failed" patients. Neurosurgery 30:897-903, 1992
41. Wilkinson SE, Parker PJ, Nixon JS: Isoenzyme specificity of bisindolylmaleimides, selective inhibitors of protein kinase C. Biochem J 294:335-337, 1993
42. Williams GT: Programmed cell death: apoptosis and oncogenesis. Cell 65:1097-1098, 1991
43. Yasuda I, Kishimoto A, Tanaka S, et al: A synthetic peptide substrate for selective assay of protein kinase C. Biochem Biophys Res Commun 166:1220-1227, 1990